Non-Small Cell Lung Cancer Video Channel
Explore the latest insights and summaries from experts in Non-Small Cell Lung Cancer.
Therapeutic Agents
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-Deruxtecan Related ILD - A Real-World Experience
FEATURING
Kelsey Natsuhara
- 1,425 views
- October 14, 2024
- 6
Fox Chase Cancer Center
Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomic Alterations
FEATURING
Joshua Reuss
- 261 views
- January 8, 2025
- 3
Oncology 2024 Year in Review
Year in Review 2024 - Top Clinical Trials in Neuro-Oncology
FEATURING
Stephen Bagley
- 299 views
- December 20, 2024
- 2
Mariam Alexander
Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of Amivantamab Combination
- 426 views
- November 8, 2024
- 2
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New Treatments
FEATURING
Guru Sonpavde
- 2,202 views
- April 16, 2024
- 12
Memorial Sloan Kettering Cancer Center
FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCLC and Pancreatic Cancer - eNRGy Study
FEATURING
Alison Schram
- 187 views
- February 12, 2025
Nebraska Oncology Society
Year in Review 2024 - Targeted Therapy for NSCLC
FEATURING
Joseph Murray
- 188 views
- January 5, 2025
- 1
Insights from 2024 WCLC
WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimertinib in 1L EGFR-Mut Advanced NSCLC
FEATURING
Shirish Gadgeel
- 365 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Developmental Therapeutics Highlights
FEATURING
Guru Sonpavde
- 320 views
- October 25, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOMA-3 Trials
FEATURING
Luis Raez
- 728 views
- June 14, 2024
- 5
Total Health
Treatment Updates in Advanced and Metastatic NSCLC - Advances in Thoracic Oncology
FEATURING
Jason Porter
- 184 views
- October 29, 2024
- 1
Northwestern Medicine Oncology and Hematology
Hyperprogression in Cancer Treated With Immunotherapy
FEATURING
Young Chae
- 1,242 views
- April 19, 2024
- 5
MI&T Congressi
Options for Osimertinib-Resistant NSCLC
FEATURING
Trever Bivona
- 212 views
- September 3, 2024
- 4
GRACE
Advancing Treatment in EGFR-Mutated NSCLC: Results From FLAURA2 and MARIPOSA Trials
FEATURING
Aakash Desai,
Fawzi Abu Rous
- 118 views
- December 1, 2024
- 1
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: NSCLC
FEATURING
Rajat Thawani
- 283 views
- August 27, 2024
- 4
Yale Cancer Center
Resectable NSCLC: Perioperative Immunotherapy and Multidisciplinary Care
FEATURING
Gavitt Woodard
- 75 views
- January 14, 2025
John Conibear
Managing EGFR-Mutant NSCLC Patients With Osimertinib Resistance
- 112 views
- November 21, 2024
- 2
Yale Cancer Center
Key Metastatic NSCLC Trial Updates Including MARIPOSA and FLAURA2
FEATURING
Sarah Goldberg
- 122 views
- October 21, 2024
- 1
UNC Lineberger Comprehensive Cancer Center
Targeted Therapies in Resected and Unresectable NSCLC
FEATURING
Shetal Patel
- 71 views
- December 3, 2024
- 1
West Virginia State Rheumatology Society
Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers
FEATURING
Jean Bustamante
- 440 views
- June 26, 2024
- 2
Luis Raez
Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage Disease
- 509 views
- May 27, 2024
- 5
Insights from 2024 WCLC
FLAURA2 Trial: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemo in EGFR-Mutated Advanced NSCLC
FEATURING
Natalia Valdivieso
- 172 views
- September 23, 2024
- 1
ecancer
ESMO and WCLC Updates on Common EGFR Mutations in NSCLC: Panel Discussion
- 87 views
- January 16, 2025
- 1
Integrity CE
Management of Stage IV NSCLC With Actionable Mutations
FEATURING
Grace Dy
- 186 views
- September 3, 2024
- 3
MI&T Congressi
ADC in Combination With Immunotherapy for NSCLC
FEATURING
Stephen Liu
- 221 views
- July 26, 2024
- 1
Lung Cancer Europe (LuCE)
Targeted Therapy and Oncogene Addiction in Lung Cancer: New Developments
FEATURING
Benjamin Besse
- 94 views
- November 11, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Developmental Therapeutics Highlights From ASCO® 2024
FEATURING
Guru Sonpavde
- 552 views
- July 5, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents in Lung Cancer
FEATURING
Pilar Garrido
- 167 views
- September 26, 2024
- 1
ecancer
Cemiplimab Monotherapy as 1L Treatment for Advanced NSCLC: EMPOWER-Lung 1 Study Results
FEATURING
Ana Baramidze
- 112 views
- November 4, 2024
- 1
Yale Cancer Center
2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertinib + Chemo vs. Osimertinib Alone for Advanced EGFRm Disease
FEATURING
Pasi Janne
- 702 views
- February 23, 2024
- 3
Fox Chase Cancer Center
Progress in Targeting ALK and ROS1 in NSCLC
FEATURING
Melina Marmarelis
- 68 views
- December 16, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: Biology of CNS Metastases in NSCLC
FEATURING
Timothy Burns
- 153 views
- September 19, 2024
- 3
Dionysis Papadatos-Pastos
Optimizing Treatment Intensification in 1L EGFR-Mutated NSCLC
- 143 views
- September 26, 2024
Federico Cappuzzo
Current & Future Directions of IO in Early Stage NSCLC
- 123 views
- October 17, 2024
- 1
MI&T Congressi
New Immune Checkpoint Inhibitors in Lung Cancer
FEATURING
Solange Peters
- 203 views
- July 25, 2024
- 1
Iris Uras
Recent Advancements in KRASG12C Inhibitors for NSCLC Treatment
- 140 views
- October 2, 2024
- 1
MI&T Congressi
Current ADC Development in NSCLC
FEATURING
Hossein Borghaei
- 188 views
- July 18, 2024
- 2
MI&T Congressi
MET Exon 14 Skipping Mutations in NSCLC
FEATURING
Oliver Gautschi
- 194 views
- July 19, 2024
- 1
GRACE
Targeted Therapy in Lung Cancer: Side Effects
FEATURING
Tejas Patil
- 106 views
- September 12, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: Highlights of Coming Advances in mNSCLC - Cytotoxics, IO, and KRAS Inhibitors
FEATURING
Brian Henick
- 119 views
- September 19, 2024
ecancer
Predicting Clinical Outcomes in mNSCLC With TROP2 Expression: Insights From TROPION-Lung01
FEATURING
Marina Garassino
- 92 views
- November 4, 2024
ecancer
ESMO 2024 Review: Amivantamab ± Chemo in EGFRm aNSCLC Post-Osimertinib - MARIPOSA-2 Interim OS
FEATURING
Enriqueta Felip
- 39 views
- January 21, 2025
Memorial Sloan Kettering Cancer Center
NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting
FEATURING
Michael Hwang
- 1,053 views
- December 13, 2023
- 13
MI&T Congressi
How the Experts Treat: Adjuvant or Neoadjuvant Immunotherapy for NSCLC
FEATURING
Tina Cascone
- 147 views
- July 24, 2024
- 2
Clarissa Mathias
TROP2, CEACAM5, and MET Antibody-Drug Conjugates in NSCLC
- 41 views
- December 2, 2024
- 1
International Cancer Imaging Society (ICIS)
Imaging of Precision Therapy in Lung Cancer
FEATURING
Mizuki Nishino
- 16 views
- February 6, 2025
MI&T Congressi
How the Experts Manage: ADC-Associated Toxicities in NSCLC
FEATURING
Natasha Leighl
- 182 views
- August 8, 2024
Fred Hutchinson Cancer Center
Practical Guidelines on Testing & Treatment of BRAF V600+ NSCLC
FEATURING
Christina Baik
- 104 views
- August 28, 2024
- 1
Lorenzo Belluomini
Clinical Insights on the Management of Edema Associated With MET Inhibitors in NSCLC
- 230 views
- June 17, 2024
- 1
Springer Healthcare IME
Targeted Therapy for NTRK Fusion-Positive Cancers
FEATURING
Alex Drilon
- 86 views
- October 1, 2024
- 1
Insights from 2024 WCLC
WCLC 2024 Insights: LAURA Study - Osimertinib After Definitive CRT in Unresectable Stage III EGFRm NSCLC
FEATURING
Terufumi Kato
- 97 views
- September 18, 2024
MI&T Congressi
Pharmacology of ADC Classes in Lung Cancer
FEATURING
Marzia Del Re
- 93 views
- August 27, 2024
- 1
MI&T Congressi
New Drugs as Maintenance Therapy After CRT in Stage III NSCLC
FEATURING
Fabrice Barlesi
- 112 views
- August 20, 2024
- 1
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Changing Systemic Therapy Post Oligoprogression in the CNS
FEATURING
Gregory Riely
- 246 views
- April 30, 2024
- 2
MI&T Congressi
How the Experts Manage: Cardiotoxicity and IO in NSCLC
FEATURING
Jordi Remon Masip
- 123 views
- August 2, 2024
Dana-Farber Cancer Institute
Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targeted Therapy in NSCLC
FEATURING
Biagio Ricciuti
- 230 views
- May 22, 2024
- 1
GRACE
Advancing Treatment in EGFR-Mutated NSCLC: Results From MARIPOSA2 and LAURA Trials
FEATURING
Aakash Desai,
Fawzi Abu Rous
- 29 views
- December 1, 2024
MI&T Congressi
Options for BRAF-Mutated NSCLC Patients
FEATURING
David Planchard
- 138 views
- July 16, 2024
MI&T Congressi
New Drugs for HER2 Deregulated NSCLC
FEATURING
Egbert Smit
- 62 views
- September 3, 2024
Moffitt Cancer Center
Future Targets for Cell Therapy in Lung Cancer: Breaking the Glass Ceiling
FEATURING
Benjamin Creelan
- 23 views
- December 6, 2024
- 1
OncoAlert
mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC
FEATURING
Charu Aggarwal
- 387 views
- February 15, 2024
- 2
Insights from 2023 ESMO Annual Meeting
PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
FEATURING
Nicolas Girard
- 842 views
- November 17, 2023
- 7
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Successes and Challenges of Early Drug Development for Brain Metastasis
FEATURING
Alex Drilon
- 311 views
- April 30, 2024
- 2
GRACE
Newer Types of Treatment for Lung Cancer: ADCs and Bispecifics
FEATURING
Lyudmila Bazhenova
- 333 views
- February 15, 2024
- 1
Integrity CE
TROP-2 ADCs for the Treatment of HR+/HER2- BC, TNBC, and NSCLC: Advancing Care in the Community Oncology Setting
FEATURING
Lee Schwartzberg,
Jason Porter
- 125 views
- March 20, 2024
- 1
MI&T Congressi
The Role of IO for Oncogene-Addicted NSCLC
FEATURING
Francesco Passiglia
- 58 views
- August 20, 2024
- 1
Insights from 2023 ESMO Asia Annual Meeting
Oncogene-Driven NSCLC: RET, NTRK, and ROS1
FEATURING
Junko Tanizaki
- 423 views
- February 7, 2024
UCLA Health
HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGFRm Advanced NSCLC
FEATURING
Aaron Lisberg
- 155 views
- May 9, 2024
- 1
Maen Hussein
Improving Outcomes in NSCLC: Treatment and Prognostication Updates
- 295 views
- February 23, 2024
- 7
Lung Cancer Europe (LuCE)
Targeted Therapy and Oncogene Addiction in Lung Cancer: Drug Access
FEATURING
Benjamin Besse
- 28 views
- November 11, 2024
- 1
MI&T Congressi
Anti-ALK NSCLC Agents as Adjuvant Therapy
FEATURING
Marina Chiara Garassino
- 86 views
- August 8, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: Cemiplimab Monotherapy in PD-L1 ≥50% Advanced NSCLC - 5-Year EMPOWER-Lung 1 Results
FEATURING
Ana Baramidze
- 51 views
- September 19, 2024
Insights from TTLC 2024 Annual Meeting
TTLC 2024 Insights: "NTRK and NRG Fusions in NSCLC"
FEATURING
Liza Villaruz
- 306 views
- March 5, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: The Global TRUST-II Study - Efficacy & Safety of Taletrectinib in Patients With ROS1+ NSCLC
FEATURING
Geoffrey Liu
- 37 views
- October 11, 2024
ecancer
ASCO® 2024 Lung Cancer Updates: CROWN, ADRIATIC, and LAURA Trials
FEATURING
Luis Raez
- 68 views
- July 2, 2024
- 1
Insights from ELCC 2024
ELCC 2024 Insights: "Vaccine-Based Therapy in Lung Cancer"
FEATURING
Marco Tagliamento
- 176 views
- April 10, 2024
ecancer
ESMO 2024 Review: Mechanisms of Acquired Resistance to 1L Amivantamab + Lazertinib vs. Osimertinib in EGFRm aNSCLC
FEATURING
Enriqueta Felip
- 17 views
- January 21, 2025
Oncology Data Advisor
Zenocutuzumab Approval: Counseling Patients With NSCLC and Pancreatic Cancer
FEATURING
Matthew Hadfield
- 26 views
- February 5, 2025
Blanca Ledezma
Practical Guidance for the Management of Adverse Events in Patients With NSCLC Receiving KRASG12C Inhibitors
- 633 views
- November 14, 2023
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Evolution Trial - RT-Free Pembro + Chemo in High PD-L1 LA-NSCLC"
FEATURING
Akito Hata
- 129 views
- June 10, 2024
- 2
MI&T Congressi
IO Long-Term Survival in Advanced NSCLC
FEATURING
Rolf A. Stahel
- 56 views
- July 25, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: PACIFIC-BRAZIL Study - Intensified Chemo-Immuno-Radiotherapy With Durvalumab for Stage III NSCLC
FEATURING
William William
- 41 views
- September 23, 2024
Total Health
Selected Targeted Therapies in NSCLC - Advances in Thoracic Oncology
FEATURING
Jason Porter
- 30 views
- October 29, 2024
2023 Evolution Conference
IO and Targeted Treatment for mNSCLC
FEATURING
Meghan Mooradian
- 466 views
- November 8, 2023
- 2
Santiago Viteri
The VISION Trial: Tepotinib in Patients With NSCLC Harboring METex14 Skipping Mutation
- 137 views
- May 10, 2024
- 1
Yale Cancer Center
Treatment Approach to ROS1 Rearranged NSCLC
FEATURING
Michael Grant
- 525 views
- October 19, 2023
- 2
MI&T Congressi
Selecting Patients for CTLA4 Therapy for NSCLC
FEATURING
Rafal Dziadziuszko
- 44 views
- July 25, 2024
Robert Hsu
Unmet Need in NSCLC Treatment Options Following Progression on 1L IO + Chemo
- 437 views
- November 15, 2023
- 4
Yale Cancer Center
Targeting Drug-Tolerant Persister Cells: Osimertinib Combinations in NSCLC
FEATURING
Pasi Janne
- 196 views
- February 23, 2024
- 1
COR2ED The Heart of Medical Education
Oncogene-Addicted NSCLC Highlights From WCLC & ESMO 2024
FEATURING
Herbert Loong
- 39 views
- October 28, 2024
ecancer
ESMO 2024 Insights: PIONeeR Trial - IO Resistance Pathways Investigated to Tailor Combination Advanced NSCLC Therapy
FEATURING
Pascale Tomasini
- 29 views
- October 11, 2024
Yale Cancer Center
GI Oncology Year in Review: Key mCRC Studies Including CheckMate 8HW & CodeBreaK 300
FEATURING
Michael Cecchini
- 115 views
- March 11, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Completely Resected NSCLC
FEATURING
Glenwood Goss
- 21 views
- October 21, 2024
Dana-Farber Cancer Institute
Updates in KRAS G12C Mutant NSCLC: Demographics, Clinical Features, Genomics, and Treatment
FEATURING
Biagio Ricciuti
- 240 views
- January 8, 2024
- 1
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "TROPION-Lung01 Study - Dato-DXd vs. Docetaxel in Previously Treated Advanced/Metastatic NSCLC"
FEATURING
Aaron Lisberg
- 325 views
- November 17, 2023
- 3
Insights from 2024 WCLC
WCLC 2024 Insights: Health-Related QoL Outcomes With Adagrasib vs. Docetaxel in KRASG12C-Mutated aNSCLC - KRYSTAL-12
FEATURING
Robert Jotte
- 21 views
- October 28, 2024
MI&T Congressi
Maintenance IO in Stage III Unresectable NSCLC
FEATURING
Anne-Marie Dingemans
- 37 views
- July 22, 2024
ecancer
ASCO® 2024 Insights: "HARMONi-A Study - Ivonescimab + Chemo for EGFRm NSCLC Patients Who Progressed on EGFR-TKI Treatment"
FEATURING
Li Zhang
- 33 views
- July 2, 2024
- 1
Insights from ELCC 2024
Advancing Lung Adenocarcinoma Treatment: Establishing KRAS-Driven Organoids for Drug Screening
FEATURING
Isa Tas
- 120 views
- April 18, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: Long-Term Follow Up on Pembro + Itacitinib in PD-L1 Positive Metastatic NSCLC
FEATURING
Melina Marmarelis
- 22 views
- September 23, 2024
Insights from 2023 WCLC
WCLC 2023 Insights: "5-Year Survival of Pembro + Chemo for mNSCLC With PD-L1 Tumor Proportion Score <1%"
FEATURING
Shirish Gadgeel
- 305 views
- October 9, 2023
- 1
Yale Cancer Center
2024 Updates on NSCLC Targeted Therapies: New Drug Targets in EGFRm Disease - TROP2
FEATURING
Pasi Janne
- 119 views
- February 23, 2024
- 2
University of Colorado Cancer Center
EGFR Exon 20 Insertion Mutations in NSCLC: Optimal and “Soon to Be Optimal” Therapy
FEATURING
Tejas Patil
- 206 views
- December 4, 2023
- 3
Northwestern Medicine Oncology and Hematology
Can Double-Lung Transplant Be a Treatment Option for Stage 4A Lung Cancers?
FEATURING
Young Chae
- 37 views
- September 3, 2024
- 1
MI&T Congressi
Adaptive Mechanisms of Resistance to G12C(OFF) Inhibitors in NSCLC
FEATURING
Chiara Ambrogio
- 27 views
- September 3, 2024
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Recent Developments in the Treatment of Patients With EGFR ex 20 Ins NSCLC"
FEATURING
Paul Mitchell
- 307 views
- November 10, 2023
- 1
ecancer
ESMO 2023 Insights: "Phase 3 CheckMate-77T Study - Perioperative Nivo + Chemo for Resectable NSCLC"
FEATURING
Tina Cascone
- 308 views
- October 25, 2023
- 6
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "RAMOSE Trial - Osimertinib+/-Ramucirumab in TKI-Naïve EGFRm mNSCLC"
FEATURING
Xiuning Le
- 229 views
- November 8, 2023
- 2
OncoPharm
Latest FDA Approvals: Ensartinib, Subcutaneous Nivolumab, and Encorafenib for NSCLC, CRC & Melanoma
FEATURING
John Bossaer
- 17 views
- February 5, 2025
ecancer
ESMO 2023 Insights: "CodeBreak 300 Phase 3 Study - Sotorasib & Panitumumab in KRAS G12Cm mCRC"
FEATURING
Filippo Pietrantonio
- 266 views
- October 27, 2023
- 1
ImmunoTherapy Bridge 2023
What’s New in NSCLC & Mesothelioma Immunotherapy
FEATURING
Alessandro Morabito
- 120 views
- January 19, 2024
- 2
GRACE
Neoadjuvant Treatment for Patients With NSCLC
FEATURING
Joshua Reuss
- 113 views
- February 13, 2024
Fox Chase Cancer Center
Special Populations in Lung Cancer: KRAS, STK11, and KEAP1 Mutations and IO
FEATURING
Suki Padda
- 8 views
- December 16, 2024
Integrity CE
The Evolving Treatment Journey for Patients With Unresectable Stage III NSCLC in the Era of Immune Therapy
FEATURING
Ticiana Leal
- 93 views
- January 26, 2024
GRACE
Key Points From the ADAURA Trial: Osimertinib in NSCLC
FEATURING
Joshua Reuss
- 108 views
- February 13, 2024
MI&T Congressi
Anti-EGFR Agents in the Adjuvant NSCLC Setting
FEATURING
Yi-Long Wu
- 30 views
- August 2, 2024
Insights from ELCC 2024
ELCC 2024 Insights: "ETOP ABC-Lung Trial - Atezo + Bev & Chemo in EGFRm NSCLC With Acquired Resistance"
FEATURING
Martin Früh
- 60 views
- April 11, 2024
Insights from 2024 WCLC
WCLC 2024 Insights: KRAS G12C Inhibitor IBI351 in Advanced NSCLC
FEATURING
Qing Zhou
- 24 views
- October 17, 2024
OncoAlert
Year in Review: Colorectal and Anal Cancers
FEATURING
Cathy Eng
- 59 views
- February 22, 2024
Louisville Hematology Highlights
Using Tumor Infiltrating Lymphocytes to Induce Solid Tumor Regression
FEATURING
Jason Chesney
- 84 views
- February 26, 2024
GRACE
Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutations
FEATURING
Lyudmila Bazhenova
- 39 views
- May 1, 2024
GRACE
Adding to Targeted Therapy in NSCLC: Current Statistics and Biology
FEATURING
Puneeth Iyengar
- 87 views
- February 13, 2024
COR2ED The Heart of Medical Education
Testing to Treatment of BRAF-Mutant Metastatic NSCLC
FEATURING
Federico Cappuzzo,
David Planchard
- 8 views
- February 3, 2025
GRACE
Antibody Drug Conjugates and How They Are Used in NSCLC
FEATURING
Lyudmila Bazhenova
- 33 views
- May 1, 2024
ImmunoTherapy Bridge 2023
Best of SITC 2023 for Clinical Development and IO Trials
FEATURING
Paolo A. Ascierto
- 94 views
- January 11, 2024
- 1
OncoAlert
Updates in Targeted Therapies for Solid Tumors
FEATURING
Benedikt Westphalen
- 66 views
- February 17, 2024
ecancer
ESMO 2023 Insights: "Phase 2 KRYSTAL-7 Trial - Adagrasib+Pembro Combo for KRASG12C+, Treatment-Naïve, Advanced NSCLC"
FEATURING
Pasi Janne
- 99 views
- October 25, 2023
Total Health
73 y/o Chinese Female With Large LUL Mass and Pleural Mets: NSCLC Molecular Tumor Board
FEATURING
Lee Schwartzberg
- 47 views
- February 28, 2024
- 1
Insights from 2023 ESMO Asia Annual Meeting
ESMO Asia 2023 Insights: "EGFR TKIs in NSCLC - Which One, How Long, When, and Who"
FEATURING
Masahiro Tsuboi
- 54 views
- January 3, 2024
- 1
ecancer
ESMO and WCLC Updates on EGFR Exon 20 Insertion in NSCLC: Panel Discussion
- 11 views
- January 21, 2025
Lorenzo Belluomini
Selpercatinib in Patients With RET Fusion-Positive NSCLC: Where Are We Now?
- 62 views
- December 22, 2023
- 1
Insights from 2023 WCLC
WCLC 2023 Insights: "Mechanisms of Resistance to KRAS G12C Inhibitors in NSCLC"
FEATURING
Biagio Ricciuti
- 98 views
- October 9, 2023
- 1
Icahn School of Medicine at Mount Sinai
PanRAF Inhibitors in NSCLC
FEATURING
Rajwanth Veluswamy
- 24 views
- May 7, 2024
Oncology Data Advisor
Additional Advances in Immune-Related Adverse Events in Lung Cancer: Research and Clinical Trials
FEATURING
Beth Sandy
- 14 views
- September 18, 2024
Insights from 2023 WCLC
WCLC 2023 Insights: "PD-L1 Subgroups in the Phase 3 LUNAR Study - TTFields and Immune Checkpoint Inhibitor in mNSCLC"
FEATURING
Rupesh Kotecha
- 72 views
- October 17, 2023
- 1
Yale Cancer Center
Breakthrough Radiotherapy as a New Option for Bone and Lung Cancer Patients
FEATURING
Kimberly Johung
- 16 views
- April 30, 2024
ecancer
ESMO 2024 Review: Safety and Antitumor Activity of Zipalertinib in EGFR Exon 20 NSCLC After Amivantamab
FEATURING
Pascale Tomasini
- 5 views
- January 21, 2025
Insights from ELCC 2024
ELCC 2024 Insights: "CIS-DPI-01 Study - Dry Powder Inhaled Cisplatin in Stage IV NSCLC"
FEATURING
Mariana Brandão
- 12 views
- April 11, 2024
ecancer
ESMO 2024 Review: Osimertinib After CRT in Unresectable Stage 3 EGFRm NSCLC - CNS and Distant Progression Results From LAURA
FEATURING
Enriqueta Felip
- 4 views
- January 21, 2025
ecancer
PROFIT Study: Use of NK-1 Inhibitor HR20013 in Preventing Chemo-Induced Nausea in Advanced NSCLC
FEATURING
Li Zhang
- 6 views
- November 4, 2024
Masonic Cancer Center, University of Minnesota
Molecular Pathways and Therapeutic Implications in Pulmonary Metastasis
FEATURING
Mark Headley
- 4 views
- December 3, 2024
GRACE
Structure and Function of ADCs in Lung Cancer
FEATURING
Alissa Cooper
- 1 view
- February 21, 2025